The Massachusetts House of Representatives has voted to create a five-year pilot program allowing the use of psychedelics to treat mental health conditions.
Under the proposal, which is part of a $561 million bond bill that was approved by a vote of 148-2 on Wednesday, “clinically appropriate patients” could use “naturally occurring psychedelic materials” for “on-site administration by a multi-disciplinary care team in a supervised licensed mental health clinic setting.”
Under the legislation, there would be a new Medical Psychedelics Fund, and the Department of Public Health would issue up to three permits to mental health clinics to participate in the program “for the purposes of establishing the best and safest clinical practices for psychedelic mental health treatment programs” and for the purposes of “collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy.”
Participating clinics could not be “subsidiaries, affiliates or members of cannabis industry organizations, psychedelic molecule development companies or pharmaceutical companies,” it says, and they would need to “track patient care outcomes data related to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic stress disorder and substance use disorder.”
The measure specifies that current state drug criminalization laws “shall not apply to the medical use
Read full article on Marijuana Moment
